-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I5DLj7o2zufDomDypfuKJ0twwQ/jrBK+AmW+NReqsZzOjtjutsh3iYEwY4Od7dJx DMghVzzZqJ+ikIrttcNm5Q== 0001144204-05-004248.txt : 20050214 0001144204-05-004248.hdr.sgml : 20050214 20050211190454 ACCESSION NUMBER: 0001144204-05-004248 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 20050214 DATE AS OF CHANGE: 20050211 GROUP MEMBERS: CANADIAN MEDICAL DISCOVERIES FUND INC. GROUP MEMBERS: MDS ASSOCIES-NEUROSCIENCE INC. GROUP MEMBERS: MDS CAPITAL (QUEBEC) INC. GROUP MEMBERS: MDS CAPITAL MANAGEMENT CORP. GROUP MEMBERS: MDS LIFE SCIENCES TECHNOLOGY FUND II NC LIMITED PARTNERSHIP GROUP MEMBERS: MDS LIFE SCIENCES TECHNOLOGY FUND II QUEBEC LIMITED PARTNERS GROUP MEMBERS: MDS LSTF II (NCGP) INC. GROUP MEMBERS: MDS LSTF II (QGP) INC. GROUP MEMBERS: MICHAEL CALLAGHAN GROUP MEMBERS: ML II CO-INVESTMENT FUND NC LIMITED PARTNERSHIP GROUP MEMBERS: MLII (NCGP) INC. GROUP MEMBERS: NEUROSCIENCE PARTNERS LIMITED PARTNERSHIP GROUP MEMBERS: SC (GP) INC. GROUP MEMBERS: SC BIOTECHNOLOGY DEVELOPMENT FUND L.P. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: RENOVIS INC CENTRAL INDEX KEY: 0001118361 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943353740 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-80111 FILM NUMBER: 05601286 BUSINESS ADDRESS: STREET 1: TWO CORPORATE DR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-266-1400 MAIL ADDRESS: STREET 1: TWO CORPORATE DR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MDS CAPITAL CORP CENTRAL INDEX KEY: 0001229595 IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FILING VALUES: FORM TYPE: SC 13G MAIL ADDRESS: STREET 1: MDS CAPITAL CORP STREET 2: 100 INTERNATIONAL BLVD CITY: TORONTO ONTARIO CANADA M9W 6J6 STATE: A6 ZIP: 0000 SC 13G 1 v012520_sc13-g.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ____)* Renovis, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.001 Par Value Per Share - -------------------------------------------------------------------------------- (Title of Class of Securities) 759885106 -------------- (CUSIP Number) November 2, 2004 - -------------------------------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |_| Rule 13d-1(b) |X| Rule 13d-1(c) |_| Rule 13d-1(d) - ---------- *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - ------------------- ------------------ CUSIP No. 759885106 13G Page 1 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Capital Corp. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 1,298,577 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 1,298,577 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,298,577 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.28% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 759885106 13G Page 2 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Capital Management Corp. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 211,277 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 211,277 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.86% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 759885106 13G Page 3 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Life Sciences Technology Fund II NC Limited Partnership - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 211,277 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 211,277 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 211,277 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.86% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------------- ------------------ CUSIP No. 759885106 13G Page 4 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Life Sciences Technology Fund II Quebec Limited Partnership - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Quebec, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 74,437 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 74,437 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 74,437 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.3% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 759885106 13G Page 5 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) ML II Co-Investment Fund NC Limited Partnership - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 142,857 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 142,857 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 142,857 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.58% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 759885106 13G Page 6 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SC Biotechnology Development Fund L.P. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 285,714 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 285,714 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 285,714 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.16% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 759885106 13G Page 7 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Canadian Medical Discoveries Fund Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Canada Federal - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 508,760 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 0 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 508,760 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 0 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 508,760 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.07% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 759885106 13G Page 8 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Neuroscience Partners Limited Partnership - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 561,693 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 561,693 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 561,693 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.29% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) PN - ------------ ------------------------------------------------------------------- - ------------------- ------------------ CUSIP No. 759885106 13G Page 9 of 24 Pages - ------------------- ------------------ - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Capital (Quebec) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 22,599 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 22,599 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 22,599 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.09% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 759885106 13G Page 10 of 24 Pages - ------------------- ------------------- - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Michael Callaghan - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 5,133 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 0 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 5,133 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 0 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,133 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.02% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) IN - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 759885106 13G Page 11 of 24 Pages - ------------------- ------------------- - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS LSTF II (NCGP) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 211,277 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 211,277 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 211,277 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.86% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 759885106 13G Page 12 of 24 Pages - ------------------- ------------------- - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS LSTF II (QGP) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Quebec, Canada - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 74,437 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 74,437 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 74,437 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.3% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 759885106 13G Page 13 of 24 Pages - ------------------- ------------------- - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MLII (NCGP) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Ontario, Canada - ------------ ------------------------------------------------------------------- - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 142,857 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 142,857 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 142,857 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.58% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 759885106 13G Page 14 of 24 Pages - ------------------- ------------------- - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) SC (GP) Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 285,714 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 285,714 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 285,714 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 1.16% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 759885106 13G Page 15 of 24 Pages - ------------------- ------------------- - ------------ ------------------------------------------------------------------- 1. NAMES OF REPORTING PERSONS/ I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) MDS Associes-Neuroscience Inc. - ------------ ------------------------------------------------------------------- 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) |_| (b) |_| - ------------ ------------------------------------------------------------------- 3. SEC USE ONLY - ------------ ------------------------------------------------------------------- 4. CITIZENSHIP OR PLACE OF ORGANIZATION Canada Federal - ------------ ------------------------------------------------------------------- NUMBER OF 5. SOLE VOTING POWER SHARES 0 BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH - ------------ --------- --------------------------------------------------------- 6. SHARED VOTING POWER 561,693 - ------------ --------- --------------------------------------------------------- 7. SOLE DISPOSITIVE POWER 0 - ------------ --------- --------------------------------------------------------- 8. SHARED DISPOSITIVE POWER 561,693 - ------------ ------------------------------------------------------------------- 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 561,693 - ------------ ------------------------------------------------------------------- 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) Not applicable |_| - ------------ ------------------------------------------------------------------- 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.29% - ------------ ------------------------------------------------------------------- 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------ ------------------------------------------------------------------- - ------------------- ------------------- CUSIP No. 759885106 13G Page 16 of 24 Pages - ------------------- ------------------- Item 1(a). Name of Issuer Renovis, Inc. Item 1(b). Address of Issuer's Principal Executive Offices Two Corporate Drive South San Francisco, California 94080 Item 2(a). Name of Person Filing This statement is filed by: (i) MDS Capital Corp. with respect to shares of common stock $.001 par value per share ("Shares") of the Issuer beneficially owned by MDS Life Sciences Technology Fund II NC Limited Partnership, MDS Life Sciences Technology Fund II Quebec Limited Partnership, MLII Co-Investment Fund NC Limited Partnership, SC Biotechnology Development Fund LP, Neuroscience Partners Limited Partnership, MDS Capital (Quebec) Inc., MDS LSTF II (NCGP) Inc., MDS LSTF (QGP) Inc., MLII (NCGP) Inc., SC (GP) Inc. and MDS Asssocies-Neuroscience Inc. (each a "Reporting Person" and collectively the "Reporting Persons"); (ii) MDS Capital Management Corp. with respect to Shares of the Issuer beneficially owned by MDS Life Sciences Technology Fund II NC Limited Partnership; (iii) MDS Life Sciences Technology Fund II NC Limited Partnership, an Ontario limited partnership, with respect to Shares beneficially owned by it; (iv) MDS Life Sciences Technology Fund II Quebec Limited Partnership, a Quebec limited partnership, with respect to Shares beneficially owned by it; (v) MLII Co-Investment Fund NC Limited Partnership, an Ontario limited partnership, with respect to Shares beneficially owned by it; (vi) SC Biotechnology Development Fund LP, a Cayman Islands limited partnership, with respect to Shares beneficially owned by it; (vii) Canadian Medical Discoveries Fund Inc., a Canadian Federal corporation, with respect to Shares beneficially owned by it; (viii) Neuroscience Partners Limited Partnership, an Ontario limited partnership, with respect to Shares beneficially owned by it; (ix) MDS Capital (Quebec) Inc., an Ontario corporation, with respect to Shares beneficially owned by it; (x) Michael Callaghan, a Canadian individual with respect to Shares beneficially owned by him; (xi) MDS LSTF II (NCGP) Inc., an Ontario corporation, with respect to Shares beneficially owned by MDS Life Sciences Technology Fund II NC Limited Partnership of which it is general partner; (xii) MDS LSTF II (QGP) Inc., a Quebec corporation, with respect to Shares beneficially owned by MDS Life Sciences Technology Fund II Quebec Limited Partnership of which it is general partner; (xiii) MLII (NCGP) Inc., an Ontario corporation, with respect to Shares beneficially owned by MLII Co-Investment Fund NC Limited Partnership of which it is general partner; (xiv) SC (GP) Inc., a Cayman Islands corporation, with respect to - ------------------- ------------------- CUSIP No. 759885106 13G Page 17 of 24 Pages - ------------------- ------------------- Shares beneficially owned by SC Biotechnology Development Fund LP of which it is general partner; and (xv) MDS Associes-Neuroscience Inc., a Canadian federal corporation, with respect to Shares beneficially owned by Neuroscience Partners Limited Partnership of which it is general partner. MDS LSTF II (NCGP) Inc., MDS LSTF II (QGP) Inc., MLII (NCGP) Inc., SC (GP) Inc. and MDS Associes-Neuroscience Inc., and MDS Capital (Quebec) Inc. are wholly owned subsidiaries of MDS Capital Corp. MDS Capital Corp. provides investment management services to Canadian Medical Discoveries Fund Inc. Michael Callaghan is an executive officer of MDS Capital Corp. As a result of certain relationships, each of the Reporting Persons may be deemed to directly and/or indirectly beneficially own up to 1,812,450 Shares, representing in the aggregate approximately 7.37% of the outstanding Shares, based on the number of Shares reported to be outstanding as of November 10, 2004 in the Issuer's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2004. Each Reporting Person disclaims beneficial ownership of any securities beneficially owned by any other Reporting Person. Due to their relationships with one another, the Reporting Persons may be deemed to constitute a "group" under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), with respect to their beneficial ownership of the Shares. The Reporting Persons, however, expressly disclaim such status and declare that the filing of this Schedule 13G is not and should not be deemed an admission that any Reporting Person, for purposes of Section 13(d) of the Act or otherwise, is the beneficial owner of the Shares held by any other Reporting Person. Item 2(b). Address of Principal Business Office or, if none, Residence The address of the principal office of (i) MDS Capital Corp. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (ii) MDS Capital Management Corp. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (iii) MDS Life Sciences Technology Fund II NC Limited Partnership is 100 International Boulevard, Toronto, Ontario M9W 6J6; (iv) MDS Life Sciences Technology Fund II Quebec Limited Partnership is 2000 Peel Street, Suite 560, Montreal, Quebec H3A 2W5; (v) MLII Co-Investment Fund NC Limited Partnership is 100 International Boulevard, Toronto, Ontario M9W 6J6; (vi) SC Biotechnology Development Fund LP is P.O. Box 897 GT, Grand Cayman, Cayman Islands; (vii) Canadian Medical Discoveries Fund Inc. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (viii) Neuroscience Partners Limited Partnership is 100 International Boulevard, Toronto, Ontario M9W 6J6; (ix) MDS Capital (Quebec) Inc. is 100 International Boulevard, Toronto, Ontario M9W 6J6 (x) Michael Callaghan is - ------------------- ------------------- CUSIP No. 759885106 13G Page 18 of 24 Pages - ------------------- ------------------- 435 Tasso Street, Suite 315, Palo Alto, California 94301-1552; (xi) MDS LSTF II (NCGP) Inc. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (xii) MDS LSTF II (QGP) Inc. is 2000 Peel Street, Suite 560, Montreal, Quebec H3A 2W6; (xiii) MLII (NCGP) Inc. is 100 International Boulevard, Toronto, Ontario M9W 6J6; (xiv) SC (GP) Inc. is P.O. Box 897 GT, Grand Cayman, Cayman Islands; and (xv) MDS Associes-Neuroscience Inc. is 100 International Boulevard, Toronto, Ontario M9W 6J6. Item 2(c). Citizenship MDS Life Sciences Technology Fund II NC Limited Partnership, MLII Co-Investment Fund NC Limited Partnership, and Neuroscience Partners Limited Partnership are Ontario limited partnerships. MDS Life Sciences Technology Fund II Quebec Limited Partnership is a Quebec limited partnership. SC Biotechnology Development Fund LP is a Cayman Islands limited partnership. Canadian Medical Discoveries Fund Inc. and MDS Associes-Neuroscience Inc. are Canadian federal corporations. Michael Callaghan is a Canadian citizen. MDS Capital Corp., MDS Capital Management Corp., MDS Capital (Quebec) Inc., MDS LSTF II (NCGP) Inc. and MLII (NCGP) Inc. are Ontario corporations. MDS LSTF II (QGP) Inc. is a Quebec corporation. SC (GP) Inc. is a Cayman Islands corporation. Item 2(d). Title of Class of Securities Common Stock, $.001 Par Value per Share Item 2(e). CUSIP Number 759885106 Item 3. Not applicable Item 4. Ownership As of the close of business on the date of filing this Schedule 13G: 1. MDS Capital Corp. (a) Amount Beneficially Owned: 1,298,577 (b) Percent of Class: 5.28% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 1,298,577 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 1,298,577 - ------------------- ------------------- CUSIP No. 759885106 13G Page 19 of 24 Pages - ------------------- ------------------- 2. MDS Capital Management Corp. (a) Amount Beneficially Owned: 211,277 (b) Percent of Class: 0.86% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 211,277 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 211,277 3. MDS Life Sciences Technology Fund II NC Limited Partnership (a) Amount Beneficially Owned: 211,277 (b) Percent of Class: 0.86% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 211,277 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 211,277 4. MDS Life Sciences Technology Fund II Quebec Limited Partnership (a) Amount Beneficially Owned: 74,437 (b) Percent of Class: 0.3% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 74,437 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 74,437 5. MLII Co-Investment Fund NC Limited Partnership (a) Amount Beneficially Owned: 142,857 (b) Percent of Class: 0.58% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 142,857 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 142,857 6. SC Biotechnology Development Fund LP (a) Amount Beneficially Owned: 285,714 (b) Percent of Class: 1.16% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 285,714 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 285,714 7. Canadian Medical Discoveries Fund Inc. (a) Amount Beneficially Owned: 508,760 (b) Percent of Class: 2.07% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 508,760 (ii) Shared power to vote or direct the vote: 0 (iii) Sole power to dispose or direct the disposition: 508,760 (iv) Shared power to dispose or direct the disposition: 0 - ------------------- ------------------- CUSIP No. 759885106 13G Page 20 of 24 Pages - ------------------- ------------------- 8. Neuroscience Partners Limited Partnership (a) Amount Beneficially Owned: 561,693 (b) Percent of Class: 2.29% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 561,693 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 561,693 9. MDS Capital (Quebec) Inc. (a) Amount Beneficially Owned: 22,599 (b) Percent of Class: 0.09% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 22,599 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 22,599 10. Michael Callaghan (a) Amount Beneficially Owned: 5,133 (b) Percent of Class: 0.02% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 5,133 (ii) Shared power to vote or direct the vote: 0 (iii) Sole power to dispose or direct the disposition: 5,133 (iv) Shared power to dispose or direct the disposition: 0 11. MDS LSTF II (NCGP) Inc. (a) Amount Beneficially Owned: 211,277 (b) Percent of Class: 0.86% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 211,277 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 211,277 12. MDS LSTF II (QGP) Inc. (a) Amount Beneficially Owned: 74,437 (b) Percent of Class: 0.3% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 74,437 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 74,437 13. MLII (NCGP) Inc. (a) Amount Beneficially Owned: 142,857 (b) Percent of Class: 0.58% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 142,857 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 142,857 - ------------------- ------------------- CUSIP No. 759885106 13G Page 21 of 24 Pages - ------------------- ------------------- 14. SC (GP) Inc. (a) Amount Beneficially Owned: 285,714 (b) Percent of Class: 1.16% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 285,714 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 285,714 15. MDS Associes-Neuroscience Inc. (a) Amount Beneficially Owned: 561,693 (b) Percent of Class: 2.29% (c) Number of shares as to which such person has: (i) Sole power to vote or direct the vote: 0 (ii) Shared power to vote or direct the vote: 561,693 (iii) Sole power to dispose or direct the disposition: 0 (iv) Shared power to dispose or direct the disposition: 561,639 Each of the above entities disclaims beneficial ownership of any securities beneficially owned by any other Reporting Person and disclaims that they are a "group" under Section 13(d) of the Act. Item 5. Ownership of Five Percent or Less of a Class Not applicable Item 6. Ownership of More than Five Percent on Behalf of Another Person Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group Not applicable Item 10. Certifications (a) Not applicable (b) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. - ------------------- ------------------- CUSIP No. 759885106 13G Page 22 of 24 Pages - ------------------- ------------------- SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of February 8, 2005. MDS Capital Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary MDS Capital Management Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary MDS Life Sciences Technology Fund II NC Limited Partnership By: MDS LSTF II (NCGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MDS Life Sciences Technology Fund II Quebec Limited Partnership By: MDS LSTF II (QGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary - ------------------- ------------------- CUSIP No. 759885106 13G Page 23 of 24 Pages - ------------------- ------------------- MLII Co-Investment Fund NC Limited Partnership By: MLII (NCGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary SC Biotechnology Development Fund LP By: SC (GP) Inc., its General Partner By: /s/ Alan Milgate By: /s/ William Walmsely ---------------------------- ----------------------- Name: Alan Milgate Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) Canadian Medical Discoveries Fund Inc. By: /s/ Anthony Flynn By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Anthony Flynn Name: Graysanne Bedell Title: Vice-President Title: Secretary Neuroscience Partners Limited Partnership By: MDS Associes-Neuroscience Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary MDS Capital (Quebec) Inc. By: /s/ Michael Mueller By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Michael Mueller Name: Graysanne Bedell Title: President Title: Secretary - ------------------- ------------------- CUSIP No. 759885106 13G Page 24 of 24 Pages - ------------------- ------------------- Michael Callaghan /s/ Michael Callaghan ---------------------------- MDS LSTF II (NCGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MDS LSTF II (QGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MLII (NCGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary SC (GP) Inc. By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS Associes-Neuroscience Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary EX-1 2 v012520_ex-1.txt Exhibit 1 Joint Filing Agreement This will confirm the agreement as of February 8, 2005 by and among all the undersigned that the Statement on Schedule 13G filed on or about this date and any further amendments thereto with respect to beneficial ownership by the undersigned of the shares of the common stock, $.001 par value per share, of Renovis, Inc., a Delaware corporation, is being filed on behalf of each of the undersigned in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934. The undersigned further agree that each party hereto is responsible for timely filing of such Statement on Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, provided that no party is responsible for the completeness and accuracy of the information concerning any other party, unless such party knows or has reason to believe that such information is inaccurate. The undersigned further agree that this agreement shall be included as an Exhibit to such joint filing. This agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. MDS Capital Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary -2- MDS Life Sciences Technology Fund II NC Limited Partnership By: MDS LSTF II (NCGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MDS Life Sciences Technology Fund II Quebec Limited Partnership By: MDS LSTF II (QGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary -3- MLII Co-Investment Fund NC Limited Partnership By: MLII (NCGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary SC Biotechnology Development Fund LP By: SC (GP) Inc., its General Partner By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) -4- Canadian Medical Discoveries Fund Inc. By: /s/ Anthony Flynn By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Anthony Flynn Name: Graysanne Bedell Title: Vice-President Title: Secretary Neuroscience Partners Limited Partnership By: MDS Associes-Neuroscience Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary MDS Capital (Quebec) Inc. By: /s/ Michael Mueller By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Michael Mueller Name: Graysanne Bedell Title: President Title: Secretary -5- Michael Callaghan /s/ Michael Callaghan ---------------------------- MDS LSTF II (NCGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MLII (NCGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary -6- SC (GP) Inc. By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS LSTF II (QGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MDS Associes-Neuroscience Inc. By: /s/ Gregory Gubitz By: /s/ Gregory Gubitz ---------------------------- ----------------------- Name: Gregory Gubitz Name: Gregory Gubitz Title: Vice-President Title: Vice-President -7- MDS Capital Management Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary EX-2 3 v012520_ex-2.txt Exhibit 2 Power of Attorney Know all by these presents, that each of the undersigned hereby constitutes and appoints each of Gregory Gubitz and Graysanne Bedell, signing singly and not jointly, as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a beneficial owner of common stock of Renovis, Inc. (the "Issuer"), the Statement on Schedule 13G and any amendments thereto, in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, and the rules thereunder; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Statement on Schedule 13G and any amendments thereto and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grant to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledge that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Issuer assuming, any of the undersigned's responsibilities to comply with Section 13 of the Securities Exchange Act of 1934 as amended. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Amendments to the Statement on Schedule 13G with respect to the undersigned's holdings of and transactions in securities issued by the Issuer, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. * * * -2- IN WITNESS WHEREOF, each of the undersigned has caused this Power of Attorney to be executed as of this 8th day of February, 2005. MDS Capital Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary MDS Life Sciences Technology Fund II NC Limited Partnership By: MDS LSTF II (NCGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MDS Life Sciences Technology Fund II Quebec Limited Partnership By: MDS LSTF II (QGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary -3- MLII Co-Investment Fund NC Limited Partnership By: MLII (NCGP) Inc., its General Partner By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary SC Biotechnology Development Fund LP By: SC (GP) Inc., its General Partner By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) Canadian Medical Discoveries Fund Inc. By: /s/ Anthony Flynn By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Anthony Flynn Name: Graysanne Bedell Title: Vice-President Title: Secretary -4- Canadian Medical Discoveries Fund Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary MDS Capital (Quebec) Inc. By: /s/ Michael Mueller By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Michael Mueller Name: Graysanne Bedell Title: President Title: Secretary -5- Michael Callaghan /s/ Michael Callaghan ---------------------------- MDS LSTF II (NCGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MLII (NCGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary -6- SC (GP) Inc. By: /s/ John Ackerley By: /s/ William Walmsely ---------------------------- ----------------------- Name: John Ackerley Name: William Walmsley Title: Directors of Cardinal Title: Director of Cardinal Investments Limited Investments Limited (Director of SC (Director of SC (GP) Inc.) (GP) Inc.) MDS LSTF II (QGP) Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President and Director Title: Secretary MDS Associes-Neuroscience Inc. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Vice-President Title: Secretary -7- MDS Capital Management Corp. By: /s/ Gregory Gubitz By: /s/ Graysanne Bedell ---------------------------- ----------------------- Name: Gregory Gubitz Name: Graysanne Bedell Title: Chief Operating Officer Title: Vice-President - Legal and Secretary -----END PRIVACY-ENHANCED MESSAGE-----